Lilly's Grupp Joins Biotech Pioneer Cephalon
Charting the future of public relations
Holmes Report
CEO

Lilly's Grupp Joins Biotech Pioneer Cephalon

Biopharmaceutical company Cephalon, best known for its narcolepsy drug Provigil, has named Robert Grupp as vice president of corporate communications.

Paul Holmes


WEST CHESTER, April 20—Biopharmaceutical company Cephalon, best known for its narcolepsy drug Provigil, has named Robert Grupp as vice president of corporate communications. Grupp, most recently director of corporate communications at Eli Lilly & Company, will be responsible for a wide range of the company’s communications activities, including media relations, employee communications, community relations, issues management and investor relations.

Grupp will report to chairman and CEO Frank Baldino, who says, “Cephalon has grown significantly over the last year, adding two new products, expanding its sales force and adding another U.S. site to its business. As a fully integrated biopharmaceutical company with diverse stakeholders, it is critical to have someone with Bob’s broad-based communications experience to help us continue to build our identity and reputation.”

The senior communications position at Cephalon has been open for approximately two years, since former VP of communications Jason Rubin left to form his own biotech communications consulting firm, The Redstone Group.

Says Grupp, “This is a terrific opportunity. It’s a 12-year-old company with three products on the market and a very rich pipeline. There are only 10 or 12 companies in the biotech arena that are making any money, and Cephalon will become one of them this year. For me, it’s an opportunity to join a smaller company where the contribution of public relations can be recognized very quickly.”

Grupp has more than 21 years of experience in public affairs and communications. Prior to Lilly, he held positions at Dow Corning Corporation and Consumers Energy Company. 

comments powered by Disqus